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INTRODUCTION
Myalgic encephalomyelitis/chronic fatigue syndrome
(ME/CFS) is a chronic, complex disease incorporating cen-
tral nervous system and immune system disorders, cell en-
ergy metabolism and ion transport dysfunction, as well as
cardiovascular abnormalities (Carruthers et al., 2011).
ME/CFS is characterised by severe chronic fatigue, accom-
panied by clinical symptoms like tender cervical or axillary
lymph nodes, muscle pain, joint pain without swelling or
redness, post-exertional malaise lasting more than 24 hours,
impaired memory or concentration, headache of a new type,
sore throat, and unrefreshing sleep (Fukuda et al., 1994).
Data on prevalence of ME/CFS varies depending on the
used diagnostic criteria. ME/CFS has been reported for
0.76% of clinically diagnosed and for 3.48% of the self-
reported population (Johnston et al., 2013).
Infectious agents, such as hepatitis C virus, human immuno-
deficiency virus, coxsackie B, Epstein-Barr virus, human
herpesvirus 6, human parvovirus B19 (B19V), borrelia,
chlamydia and mycoplasma, have been associated with
ME/CFS. However, involvement of a single specific infec-
tious agent in ME/CFS development has not been estab-
lished (Nicolson, 2002; Chapenko et al., 2006; Bansal et al.,
2012; Chapenko et al., 2012).
B19V is an immunomodulating virus of the Parvoviridae
family, Parvovirinae subfamily and Erythrovirus genus. It
was first discovered in 1975 in blood serum of a healthy do-
nor (Cossart et al., 1975). The B19V genome consists of
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Our aim was to estimate the presence of B19V infection markers, the level of cytokines and time
period since the appearance of infection in association with ME/CFS clinical symptoms. In 200
ME/CFS patients and 104 control group individuals the presence of B19V-specific IgG/IgM class
antibodies, B19V NS1 gene sequence, mRNA expression, viral load and level of cytokines were
determined. B19V-specific IgG-antibodies were found in 70% of ME/CFS patients and 67.4% of
controls, IgM-antibodies in 8% of patients and in none of controls, B19V genomic sequences in
29% of patients and 3.8% of controls. 58.6% of positive patients had active and 41.4% had la-
tent/persistent B19V infection. B19V NS1 gene expression was detected in 43% of patients.
B19V load varied from < 0.2 copies to median 38.2 copies/µg of DNA. According to the antibody
pattern, 36% of patients had a recent, and 43% had sustained B19V infection. Patients with the
B19V genomic sequence and NS1 specific antibodies significantly more often had lymphadeno-
pathy and multi-joint pain. Onset of the symptoms corresponded to time of appearance of B19V
infection. IL-10 and TNF- levels were higher in patients with elevated B19V load. B19V genome
1 was identified in Latvian ME/CFS patients. The results indicated that at least in some cases
B19V infection plays an important role in ME/CFS development
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linear single-stranded DNA, 5596 bases in length. The right
side of the virus genome codes viral capsid proteins VP1
and VP2. B19V genome encodes also small proteins of 7.5
and 11 kDa and non-structural protein NS1, which partici-
pates in production of infectious virus by regulating tran-
scription and participating in replication (Ozawa et al.,
1987; Momoeda et al., 1994; Luo and Qiu, 2015). The pres-
ence of B19V antibodies against NS1 indicate a severe and
persistent B19V infection (von Poblotzki et al., 1995). The
virus replicates mainly in primary target cells — erythroid
progenitor cells in the bone marrow. However, B19V recep-
tor (globoside), the antigenic determinant within the P
blood group, is expressed not only on erythroblasts, but also
on megakaryocytes, heart tissue, liver, lungs, kidneys, endo-
thelium, aorta and gastro-intestinal smooth muscle tissues
and synovium (Brown et al., 1993; Morey et al., 1993;
Soderlund-Venermo et al., 2002). B19V can be detected
also in non-erythroid cells and cells without P antigen
(Munakata et al., 2006). 5 and Ku80 have been reported
as B19V co-receptors (Luo and Qiu, 2015).
B19V has been frequently detected in children and young
people, and therefore 60 to 80% of adults have antibodies
against B19V (Cooling et al., 1995). B19V can cause infec-
tious erythema, arthralgia, anaemia, aplastic crisis with re-
duced red blood cell lifespan and aplasia in immunocom-
promised patients, hydrops fetalis, various skin lesions,
neutropenia, papular-purpuric gloves and socks syndrome,
hepato-biliary diseases, cardiac syndromes, autoimmune
and neurologic diseases (Kerr, 2000; Kerr, 2016).
After primary infection, B19V can remain in the body.
Therefore, its association with different clinical manifesta-
tions has been studied, including encephalitis, encephalopa-
thy, arthritis, autoimmune processes, fatigue and myalgic
encephalomyelitis (Kerr and Tyrrell, 2003; Barah et al.,
2014). B19V has been considered as one of possible trigger
factors for ME/CFS (Appel et al., 2007).
The aim of this study was to determine the relationship be-
tween incidence of B19V infection markers, level of cytoki-
nes, the period of time from B19V infection onset in
ME/CFS patients and disease clinical course.
MATERIALS AND METHODS
Patients and controls. Two hundred patients from Latvia
[130 (65%) female and 70 (35%) male, mean age 38 ± 12]
with clinically diagnosed ME/CFS corresponding to criteria
of 1994 Fukuda Centres for Disease Control and Prevention
(CDC) and 104 apparently healthy individuals from Latvia
were enrolled in this cross-sectional study. The study was
conducted according to safety standards and the cohort was
established with the approval of the Ethics Committee of
Rîga Stradiòð University. All enrolled patients gave their in-
formed consent prior to the study.
B19V specific antibody detection. Presence of B19V spe-
cific IgM and IgG class antibodies were detected in blood
plasma using commercially available recomWell and re-
comLine Parvovirus B19 IgM and IgG kits (Mikrogen
Diagnostik, Germany). Presence of specific antibodies
against six antigens of B19V [Vp-2p — main capsid anti-
gen (conformation epitope); VP-N — N-terminal half of the
structure proteins VP-1 and VP-2; VP-1S — specific seg-
ment (differentiation to VP-2); VP-2r — main capsid anti-
gen (linear epitope); VP-C — C-terminal half of the struc-
ture proteins VP-1 and VP-2; NS-1 — non-structure
protein] was determined, and the obtained reaction patterns
allowed to determine the period of time since appearance of
B19V infection (Pfrepper et al., 2005). For example, an in-
fection that had appeared a long time ago (months to years)
often shows IgG reactivity against VP-2p and/or VP-N
(usually with VP-1S). A recent infection (a few weeks to
months) shows strong IgG reactivity against VP-C and pres-
ence of anti-VP-2r can be accompanied by anti-VP-2p,
anti-VP-N and anti-VP-1S (Pfrepper et al., 2005). Presence
of B19V specific NS1 antibodies and genomic sequence
shows a persistent B19V infection (von Poblotzki et al.,
1995).
Cytokine level detection. Level of cytokines was estimated
in blood plasma according to manufacturers’ protocols us-
ing enzyme-linked immunosorbent assays (ELISA): IL-4 —
Endogen Human ELISA kit (Pierce Biotechnology,
Rockford, IL, USA), TNF- — Biorbyt Human TNF
ELISA kit (Biorbyt, United Kingdom), IL-6 – eBioscience
Human IL-6 Platinium ELISA, IL-10 — eBioscience Hu-
man IL-10 Platinium ELISA, and IL-12 (p70) —
eBioscience Human IL-12p70 Platinium ELISA
(eBioscience Europe/International, Austria).
Nucleic acid preparation. DNA was extracted from whole
peripheral blood and cell-free blood plasma by phe-
nol-chloroform extraction method. RNA was extracted from
peripheral blood mononuclear cells (PBMCs) using Tri Re-
agent (Applied Biosystems, USA). Quantity of extracted
DNA and RNA was measured spectrophotometrically.
Quality of RNA was determined in agarose gel and using
complementary DNA (cDNA) synthesised with a RevertAid
First Strand cDNA Synthesis Kit (Thermo Scientific, USA).
To assure the quality of cDNA and DNA from peripheral
blood, and to exclude possible contamination of plasma
DNA by cellular debris DNA, -globine polymerase chain
reaction (PCR) was carried out. Potential cross-contamina-
tion during extraction and PCR was prevented by process-
ing samples in separate rooms and including a negative con-
trol (DNA without the B19V genomic sequence) in each
assay and a water control after every third sample.
Polymerase chain reactions. The B19V NS1 gene se-
quence was detected in DNA isolated from peripheral blood
and cell free blood plasma by nested PCR (nPCR) accord-
ing to Barah et al., 2001 protocol and primers (Barah et al.,
2001). B19V NS1 gene expression was detected using re-
verse transcription PCR (RT-PCR) according to Ito et al.,
2013 protocol and primers (Ito et al., 2013). Amplification
products were analysed electrophoretically in agarose gel.
Viral load was estimated by real-time PCR with a Parvovi-
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rus B19 Real-TM Quant kit (Sacace Biotechnologies, Italy)
according to manufacturer’s protocol.
Phylogenetic analysis. B19V positive PCR products were
purified and sequenced with an ABI Prism 3100 Genetic
Analyzer (Applied Biosystems, USA). Part of B19V NS1
genes was aligned by phylogenetic analysis (Tamura et al.,
2013). To ensure the consistency of tree topologies, phylo-
genetic trees were reconstructed (Guindon et al., 2010; Ta-
mura et al., 2013). The robustness of the phylogenetic trees
was statistically evaluated by bootstrap analysis with 1000
replicates. The bootstrap value 75% was considered indicate
a monophyletic group.
Data analysis. Statistical analysis was conducted with
GraphPad Prism 6.0 (Chi-square, Fisher’s exact and
Mann–Whitney nonparametric tests). A value of p < 0.05
was considered to be statistically significant.
RESULTS
B19V specific IgG class antibodies were found in 70%
(140/200) of ME/CFS patients and 67.4% (60/89) of appar-
ently healthy individuals blood plasma samples (p =
0.6803). None of the control group individuals had B19V
specific IgM class antibodies while 8% (16/200) of
ME/CFS patients were IgM class antibody positive (p =
0.0018); 2.5% (5/200) had only IgM class antibodies and
5.5% (11/200) had both IgG and IgM class antibodies (p =
0.1695 and p = 0.0184, respectively).
B19V genomic sequences in DNA isolated from whole
blood were found in 29% (58/200) of patients and in 3.8%
(4/104) of controls (p < 0.0001). 58.6% (34/58) of B19V
positive ME/CFS patients and 50% (2/4) of controls had vi-
ral genomic sequences in DNA isolated from cell-free blood
plasma, while 41.4% (24/58) of patients and 50% (2/4) con-
trols had negative PCR in plasma DNA. B19V NS1 gene
expression was detected in 43% (25/58) of ME/CFS pa-
tients. Considering that the virus genomic sequence was de-
tected in DNA isolated from whole peripheral blood but not
in DNA from cell free blood plasma, the virus genomic se-
quence was located in peripheral blood leukocytes (PBL).
Therefore, the presence of B19V genomic sequence in DNA
isolated from peripheral blood, and the DNA isolated from
cell free blood plasma being negative, indicates a latent/per-
sistent B19V infection in 12% (24/200) of patients with
ME/CFS and 1.9% (2/104) of apparently healthy individu-
als (p = 0.002). However, an active B19V infection (B19V
genomic sequence detected in peripheral blood DNA as
well as in DNA from cell-free blood plasma) was found in
17% (34/200) patients with ME/CFS and 1.9% (2/104) of
apparently healthy individuals (p < 0.0001) (Fig. 1).
RT-PCR B19V NS1 gene expression in PBMCs was de-
tected in 25 of 58 ME/CFS patients who had B19V genomic
sequences in whole blood DNA. Elevated viral load was de-
tected in 20 ME/CFS patients (11 with viral genomic se-
quences in PBL and plasma DNA, 9 in PBL DNA only) and
in none of the apparently healthy individuals (p = 0.0003).
The viral load in nine of 24 patients with a latent/persistent
B19V infection (viral genomic sequences in PBL DNA)
was [median (interquartile range - IQR)] 5.6 (27.4–0.8) cop-
ies/µg DNA and in 15 patients was < 0.2 copies/µg DNA. In
addition, in 11 of 34 patients with an active B19V infection
(viral genomic sequences also in plasma DNA) the viral
load was 38.2 (217.5–17.7) copies/µg DNA and in 23 pa-
tients was < 0.2 copies/µg DNA. All apparently healthy in-
dividuals with B19V infection had a viral load < 0.2 cop-
ies/µg DNA (median viral load of a latent/persistent vs an
active B19V infection — p = 0.0289).
The B19V specific antibody reaction patterns of 75 ran-
domly selected ME/CFS patients (39 with and 36 without
the presence of B19V genomic sequence in DNA from
whole blood) with a recomLine kit showed an acute B19V
infection in one patient and a recent infection (weeks to
months after B19V infection appearance) in 41% (16/39) of
patients with B19V genomic sequence and in 30.6% (11/36)
without the sequence (p = 0.4706). A sustained infection
(months to years after B19V infection appearance) was ob-
served in 56.4% (22/39) of patients with and 27.8% (10/36)
and without the B19V genomic sequence in whole blood
DNA (p = 0.0191) (Fig. 2). 41.7% (15/36) of patients with-
out the B19V genomic sequence did not have B19V specific
antibodies, which indicates that they had never been in-
fected with B19V. A severe course of ME/CFS was experi-
enced by 18.5% (5/27) of patients with a recent B19V infec-
tion and 28.1% (9/32) with a sustained infection. 51.3%
(20/39) of the patients with the B19V genomic sequence in
DNA isolated from whole blood had B19V specific NS1 an-
tibodies.
In ME/CFS patients without an elevated B19V load, the
IL-6 level was 2.2 (4.5–1.5) pg/ml [median (IQR)] and
with elevated B19V load — 4.7 (14–2.7) pg/ml (p =
0.1525). The TNF- level in patients without and with ele-
vated B19V load was 69.9 (124.7–34.5) and 143
Fig. 1. Presence of B19V NS1 genomic sequence in DNA from peripheral
blood cells and both peripheral blood and cell free blood plasma from pa-
tients with ME/CFS and apparently healthy individuals, WB – whole blood
DNA; PBL – peripheral blood leukocyte DNA; PL – cell free plasma
DNA; ME/CFS – myalgic encephalomyelitis/chronic fatigue syndrome;
AHI – apparently healthy individuals.
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(205.5–69.1) pg/ml, respectively (p = 0.0463). The IL-10
level in patients without an elevated B19V load was 11
(19.5–5) pg/ml and with elevated B19V load — 20 (80–9.9)
pg/ml (p = 0.0509). The IL-12 level in patients without and
with elevated B19V load was 14.2 (15.8–11.7) and 15.5
(18.6–10.2) pg/ml, respectively (p = 0.4166) (Fig. 3). The
IL-4 level in all cases was < 2 pg/ml.
Figure 4 shows the percentage of ME/CFS typical clinical
symptoms in the observed patients with and without detect-
able NS1 antibodies in the presence of B19V genomic se-
quence in whole blood DNA. Of them, 55% of patients with
and 21.1% without NS1 antibodies had multi-joint pain (p =
0.0294). Muscle pain was experienced by 65% and 42.1%,
while lymphadenopathy in 65% of patients with and 31.6%
without NS1 antibodies, respectively (p = 0.1517 and p =
0.0369).
The onset of ME/CFS symptoms was determined six
months up to three years before inclusion in the study. In
93.3% (70/75) of the cases onset of symptoms had occurred
before 8.3 ± 1.7 months and in 6.7% (5/75) symptoms had
started before 28.8 ± 5.9 months. In patients with a recent
B19V infection, symptoms had started before 8.3 ± 1.6
months and with a sustained infection — 12.1 ± 7.8 months
earlier (from them 25% — more than 12 months earlier).
Fig. 2. Infection status after B19V infection onset in ME/CFS patients with
and without presence of B19V genomic sequence in DNA from peripheral
blood and/or blood plasma [* shows statistically significant result by
Fisher’s exact test (p < 0.05)].
Fig. 3. Level of cytokines in ME/CFS pa-
tients with and without elevated B19V load,
p value was estimated using the Mann-Whit-
ney nonparametric test [WE – without ele-
vated B19V load, E – with elevated B19V
load].
Fig. 4. Number of ME/CFS typical symp-
toms in patients with presence of B19V
genomic sequence with and without B19V
specific NS1 antibodies [* shows statistically
significant result by the Chi-square test (p <
0.05)].
414 Proc. Latvian Acad. Sci., Section B, Vol. 73 (2019), No. 5.
Although two B19V genotypes (genotype 1 and 2) were re-














GTTATAACCAGC) showed genotype 1 circulation in pa-
tients with ME/CFS (Fig. 5). The majority of Latvian iso-
lates (also from patients with diagnoses other than
ME/CFS) were clustered with genotype 1. Consistent tree
topologies were observed with both of neighbour-joining
and maximum likelihood methods. The gene diversity for
genotype 1 was low — 0.3~1.1%.
DISCUSSION
ME/CFS is a multifactorial disease accompanied by severe
chronic fatigue without pathophysiological explanation,
which reduced or loss of ability to work. There is no con-
sensus on presence, form and the level of immune dysfunc-
tion in case of ME/CFS (Bansal et al., 2012). ME/CFS of-
ten commences with prolonged stress or virus infection,
which is considered as one of possible ME/CFS causal
agents due to the fact that most of patients report sudden
start of illness with “flu-like” infection symptoms. Some vi-
ral infections can result in post-infectious fatigue and many
patients with ME/CFS have immunological disturbances
that could result from virus infection or be promoted by the
infection. However, involvement of virus infection in aetio-
pathogenesis of ME/CFS remains ambiguous (Morinet and
Corruble, 2012).
In this study, the frequency of B19V specific IgG class anti-
bodies was similar in patients with ME/CFS (70%) and ap-
parently healthy individuals (67.4%) (p = 0.6803). While
none of the apparently healthy individuals lacked IgM class
antibodies, 8% of patients with ME/CFS had detectable
IgM class antibodies (p = 0.0018). The obtained results in
this study are in accordance with other researchers’ findings
of a lack of a significant difference in B19V IgG class anti-
body frequency between patients and a control group. Some
researchers reported that the B19V seroprevalence in the
population varies from 60 to 80% (Cooling et al., 1995), but
others showed B19V specific IgG class antibodies in 74%
and IgM class antibodies only in one patient with ME/CFS
(Zhang et al., 2010). Kerr with colleagues analysed markers
for B19V infection in 200 apparently healthy individuals
and 200 patients with ME/CFS, and showed no difference
in B19V seroprevalence between these two groups (anti-
B19V VP2 IgG class antibodies were detected in 75% and
78%, respectively). Presence of anti-B19V VP2 IgM class
antibodies was reported in four ME/CFS patients (Kerr et
al., 2010), which is typical also for general population
(Zhang et al., 2010). It is known that B19V seroprevalence
increases with age — from 2% in children less than five
Fig. 5. Phylogenetic tree of human
parvoviruses B19V based on the NS1
gene (396 bp). The phylogenetic tree
was constructed using the maximum
likelihood method. Only posterior
probabilities values above 90% are
shown. CFS209-Latvia-09 represents
the isolate from a Latvian ME/CFS pa-
tient.
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years old up to 85% in older people (Servant-Delmas et al.,
2010). Considering the mean age of our study cohort (38 ±
12 years), the results are in accordance with the general
population worldwide.
Data of our study showed the presence of B19V NS1 spe-
cific antibodies in 20/39 (51.3%) of the ME/CFS patients,
indicating the persistence of B19V infection. The results are
similar to those reported by Kerr and co-authors, who de-
tected IgG class antibodies against NS1 protein more fre-
quently in patients with ME/CFS (41.5%) than in healthy
controls (7%) and showed a relationship with a high level
of expression of CFS-associated NHLH1 and GABPA
genes. In that study anti-B19V NS1 IgM class antibodies
were detected in three patients and one control group donor.
Presence of B19V NS1 antibodies indicates a severe and
persistent B19V infection, thereby in some patients, the im-
mune system cannot sufficiently control the virus (von
Poblotzki et al., 1995; Kerr et al., 2010).
In our study the frequency of B19V genomic sequence pres-
ence was higher in patients with ME/CFS (29%) than in ap-
parently healthy individuals (3.8%) (p < 0.0001). In case of
a latent/persistent B19V infection (B19V genomic sequence
only in DNA from PBL), a significant difference was found
between patients (12%) and apparently healthy individuals
(1.9%) (p = 0.002). Moreover, an active B19V infection
(B19V genomic sequence also in DNA from cell free blood
plasma) was detected significantly more often in patients
with ME/CFS (17%) comparing with apparently healthy in-
dividuals (1.9%) (p < 0.0001). In addition, B19V NS1 gene
expression occurred in patients with a persistent B19V in-
fection, indicating virus replication in patient PBMCs.
Other studies also reported the detection of B19V DNA,
mRNA and protein in macrophages, T cells, B cells, follicu-
lar dendritic cells and monocytes (Takahashi et al., 1998),
however B19V infection of the monocyte cell line U937
was shown to be abortive due to a lack of viral particle pro-
duction (Munakata et al., 2006).
The majority of B19V infections worldwide are caused by
B19V genotype 1. Genotypes 2 and 3 have 10% nucleotide
divergence from genotype 1. A higher frequency of geno-
type 2 has been observed among European individuals born
before 1970s. However, genotype 3 circulates mainly in
French, Brazilian, and Ghana individuals (Corcoran et al.,
2010). Analysis of the B19V sequences from the National
Centre for Biotechnology Information database obtained in
several countries worldwide, this study for the first time
showed B19V genotype 1 circulation in Latvian patients
with ME/CFS.
The obtained results in this study coincide with findings of
other researchers who showed that in a part of patients,
B19V could be involved in ME/CFS development, based on
detection of B19V infection markers in 40% of patients and
almost 15% of apparently healthy individuals (Fremont et
al., 2009). In our study, the frequency of elevated viral load
was detected significantly more often in patients with
ME/CFS compared to that in apparently healthy individuals
(p = 0.0003). Furthermore, the viral load was higher in pa-
tients with an active B19V infection than in with a
latent/persistent B19V infection (p = 0.0289). Published
studies using real-time PCR also reported that the B19V ge-
nomic sequence occurred in patients with ME/CFS but not
in control group blood donors (Kerr et al., 2010). However,
some researchers reported no association of B19V infection
with this disease, as B19V was not found in all ME/CFS
cases (Sanders and Korf, 2008). It should be noted that in
Brazil, the B19V genomic sequence was not detected in 141
Brazilian children with Exanthema subitum, by the age of
four (Magalhaes Ide et al., 2011). Reviewing neurological
aspects of B19V infection, nine reports found an association
of ME/CFS with acute B19V infection, while two studies
did not find such an association (Barah et al., 2014).
During a relatively recent or early infection phase, IgG re-
activity against B19V VP1 linear epitopes, VP2 conforma-
tional and linear epitopes is present. After six months, IgG
response to VP2 linear epitopes decreases; therefore, in the
case of a sustained infection, antibodies against VP1 linear
epitopes and VP2 conformational epitopes are present
(Soderlund et al., 1995; Manaresi et al., 1999; Modrow and
Dorsch, 2002; Pfrepper et al., 2005). Determination of
B19V IgG and IgM class antibody patterns indicated an
acute infection in one patient with ME/CFS. The antibody
reaction pattern of a recent infection occurred more often in
patients with the B19V genomic sequence (41%) than with-
out it (30.6%), however without statistical significance (p =
0.4706). However, a sustained infection occurred signifi-
cantly more often in patients with (56.4%) the B19V ge-
nomic sequence in DNA from whole blood than without it
(27.8%) (p = 0.0191). The presence of virus-specific IgG
class antibodies in absence of the genomic sequence shows
a past infection, while the presence of antibodies against
B19V and B19V genomic sequence indicates a persistent
B19V infection (Hemauer et al., 2000). Data shows that
B19V infection can persist for years. A recent and sustained
B19V infection was found in 36% and 43% of the patients,
respectively. It corresponds to the onset of ME/CFS typical
clinical symptoms (patients with a recent B19V infection —
before 8.3 ± 1.6 months and with a sustained infection —
12.1 ± 7.8 months ago) indicating B19V infection as a trig-
ger of the disease. Moreover, a severe clinical course of
ME/CFS was experienced by more patients with a sustained
B19V infection (28.1%) than with a recent infection
(18.5%) showing disease progression.
The level of pro-inflammatory cytokines IL-6 and IL-12
was higher in patients with an elevated B19V load than
without it. Moreover, TNF- and IL-10 levels were signifi-
cantly higher in patients with an elevated B19V load (p =
0.0463 and p = 0.0509, respectively). The IL-4 level was
not elevated in patients with ME/CFS. Viral infection in-
duced a prolonged state of immune disbalance, accompa-
nied by changes in the cytokine level, which might be the
cause of ME/CFS clinical symptoms. The findings of our
study are in concordance with previous reports indicating
that Th1/Th2 cytokine response imbalance is reflected by
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increase of TNF- and IL-10 levels, suggesting a persistent
chronic infection (Couper et al., 2008; Brenu et al., 2011).
Increased production of TNF- and IL-6 have also been re-
ported in case of B19V infection (Kerr et al., 2001; Kerr
and Tyrrell, 2003; Munakata et al., 2006).
According to CDC criteria, chronic fatigue is observed in
all patients with ME/CFS. In this study patients with the
B19V genomic sequence and antibodies to NS1 protein had
significantly more frequently multi-joint pain (55%) than
patients with the B19V genomic sequence and without NS1
antibodies (21.1%) (p = 0.0294). Also, muscle pain and
lymphadenopathy were more frequently observed in pa-
tients with (65% and 65%) than without (42.1% and 31.6%)
presence of NS1 antibodies (p = 0.1517 and p = 0.0369, re-
spectively). Such B19V associated clinical manifestations
as fatigue, lymphadenopathy, joint and muscle pain in pa-
tients with ME/CFS could be consequences of the virus in-
fection. Since B19V can cause typical clinical symptoms of
ME/CFS, some studies report that this virus is one of the
trigger factors for at least part of ME/CFS patients (Matano
et al., 2003; Appel et al., 2007; Fremont et al., 2009), which
coincides with the results of our study.
ME/CFS can be caused by various factors, and some viruses
or other infectious agents may contribute to a subset for this
disease, confirming the hypothesis of B19V as a trigger fac-
tor for ME/CFS (Kerr et al., 2010).
In our study, an active B19V infection was found signifi-
cantly more frequently and with a higher viral load among
patients with ME/CFS than apparently healthy individuals
and a part of typical ME/CFS clinical symptoms were asso-
ciated with B19V infection, indicating the importance of
this infection in ME/CFS development and clinical course.
Therefore, markers of B19V infection could be used as one
of biomarkers in ME/CFS diagnostics.
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CILVÇKA PARVOVÎRUSA B19 INFEKCIJAS SAISTÎBA AR MIALÌISKÂ ENCEFALOMIELÎTA / HRONISKÂ NOGURUMA
SINDROMA ATTÎSTÎBU UN KLÎNISKO GAITU
Pçtîjuma mçríis bija noteikt cilvçka parvovîrusa B19 (B19V) infekcijas maríieru klâtbûtni, citokînu lîmeni un laiku no infekcija sâkuma,
saistîbâ ar ME/CFS klîniskajiem simptomiem. 200 ME/CFS pacientiem un 104 kontroles grupas indivîdiem noteica B19V-specifisko
IgG/IgM klases antivielu un B19V NS1 gçna secîbu klâtbûtni, mRNS ekspresiju, vîrusa slodzi un citokînu lîmeni. B19V-specifiskâs IgG
klases antivielas atrada 70% no ME/CFS pacientiem un 67,4% no kontrolçm, IgM klases antivielas — 8% no pacientiem un nevienam no
kontroles grupas, bet B19V genoma secîbas — 29% no pacientiem un 3,8% no kontrolçm. 58,6% no pozitîvajiem pacientiem bija aktîva,
bet 41,4% — latenta/persistenta B19V infekcija. B19V NS1 gçna ekspresiju konstatçja 43% no pacientiem. B19V slodze bija no < 0,2 lîdz
38,2 kopijâm/µg DNS. Saskaòâ ar antivielu spektru, nesen pârciesta infekcija bija 36%, bet ilgstoða infekcija — 43% no pacientiem.
Limfadenopâtija un locîtavu sâpes bûtiski bieþâk bija pacientiem ar B19V genoma secîbu un NS1 antivielâm. ME/CFS simptomu sâkðanâs
laiks atbilst B19V infekcijas parâdîðanâs laikam. IL-10 un TNF- lîmenis bija augstâks pacientiem ar paaugstinâtu B19V slodzi. ME/CFS
pacientiem Latvijâ atklâta B19V genoma 1 klâtbûtne. Rezultâti liecina, ka vismaz daïâ gadîjumu B19V infekcijai ir svarîga loma ME/CFS
attîstîbâ.
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